 The overall objective of this pilot study is to collect immunological and safety data that will be used to decide whether a larger study of clinical efficacy is warranted in these patients. All patients on the study will be followed for a minimum of 2 years, so that the actual 2-year overall survival OS, 6-month and 2-year progression-free survival PFS rates can be determined in an exploratory manner. 